| Bioactivity | MPAK13-IN-1 is a MAPK13 (p38δ) inhibitor, with an IC50 of 620 nM. | ||||||||||||
| Invitro | MPAK13-IN-1 exhibits an IC50 of 4.63 μM in vero E6 cells[2]. Cell Viability Assay[2] Cell Line: | ||||||||||||
| Name | MAPK13-IN-1 | ||||||||||||
| CAS | 229002-10-2 | ||||||||||||
| Formula | C20H23N5O2 | ||||||||||||
| Molar Mass | 365.43 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Yurtsever Z, et al. First comprehensive structural and biophysical analysis of MAPK13 inhibitors targeting DFG-in and DFG-out binding modes. Biochim Biophys Acta. 2016 Nov;1860(11 Pt A):2335-2344. [2]. Mehdi Bouhaddou, et al. The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell. 2020 Aug 6;182(3):685-712.e19. |